Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1164/rccm.201706-1105LE | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.
J Natl Cancer Inst
December 2024
Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Background: The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression profile of patients with early-stage HER2-negative ER-low (ER 1%-9%) BC, comparing them to ER-negative (ER <1%) and ER-intermediate (ER 10%-50%) tumors.
Methods: Among 921 patients with early-stage I-III, ER ≤50%, HER2-negative BCs, tumors were classified as ER-negative (n = 712), ER-low (n = 128), or ER-intermediate (n = 81).
Reply to Editorial Comment on "Effect of USMLE Score Cutoffs on Recruitment of Underrepresented Applicants in the Urology Match".
Urology
May 2024
Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. Electronic address:
Reply to Salvi and Ghorpade: -Scores or Fixed Cutoff Values to Interpret Oscillometry: Opportunities from the LEAD Study.
Am J Respir Crit Care Med
May 2024
Ludwig Boltzmann Institute for Lung Health, Vienna, Austria.
Controlled attenuation parameter for the assessment of fatty liver in patients with type 1 diabetes mellitus: which cutoffs to choose? Authors' reply.
Pol Arch Intern Med
January 2024
Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznań, Poland
Measuring Quality of Life: Incorporating Objectively Measurable Parameters within the Cross-Sectional Bern Cohort Study 2014 (BeCS-14).
Int J Environ Res Public Health
January 2024
University Clinic Bern, Division of Gynecological Endocrinology and Reproductive Medicine, University Women's Hospital, Inselspital Bern, Friedbühlstrasse 19, 3010 Bern, Switzerland.
Up until now, the measurement of Quality of Life (QoL) was based on validated subjective rating tools rather than objective measurement. To become more independent of the self-assessment of probands, a way to objectively measure QoL should be found. A monocenter, cross-sectional, observational, non-interventional trial was performed from 2012 to 2014 at Inselspital Bern to evaluate the bio-functional status (BFS), a complex, generic, non-invasive, sex- and age-validated assessment tool, in a wide range of areas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!